News and press
Venture Leader Medtech
Every year, Venturelab selects the ten most promising Swiss startups for each of the verticals; this fall, Metadvice will join the Swiss National Startup Team for a unique opportunity to expand the global network in the US with a road show 4-8 November, 2024 in Boston.
Read more here.
Metadvice at the European Society of Cardiology, London
The Metadvice will contribute to the European Society of Cardiology Congress, 30 August – 2 September 2024 in London.
Entitled ‘Comorbidity neural network model for personalised recommendations in cardiometabolic risk factor management: towards early precision medicine in routine clinical practice’, the work discusses why a neural network can formulate therapy recommendations beyond clinical guidelines to improve comorbid outcomes for persons in primary care.
Visit the ePoster during the “Machine learning in preventive cardiology” session, at Station 4 – Research Gateway, on 31st August, 10:00 – 10:50 am UK time.
Read the full abstract here.
Independent Evaluation finds Metadvice AI is an Effective Tool for Reducing Clinician Workload in UK Primary Care
Unity Insights was commissioned by Health Innovation Kent Surrey Sussex, facilitated by the Office of Life Sciences commission, to evaluate the application of the Metadvice artificial intelligence (AI) precision clinical guidance tool within the Ball Tree Surgery in Lancing and Sompting PCN.
The evaluation concluded that Metadvice solution is considered by its users to be an effective tool for reducing clinician workload having identified potential workforce efficiency savings of over £60,000 annually if used in all CVD-related GP and pharmacist appointments at Ball Tree Surgery.
Read more here.
Metadvice AI-Powered Solution for Diabetes Management Wins the HIN & SHS Innovation Challenge
Metadvice is proud to have been awarded first place in the HIN & SHS Innovation Challenge for their AI-powered solution for diabetes management. The award from Health Info Net AG (HIN) in collaboration with Swiss Healthcare Startups (SHS) has been introduced to drive innovation and the digital transformation of the Swiss healthcare sector.
An expert jury judged the awards based on criteria including the level of innovation and contribution to the digitalization of the healthcare sector. The Metadvice solution was of particular note due to the potential of the diabetes management solution for GPs to relieve pressure on hospitals, along with its potential to support a larger number of comorbid conditions.
Read more here.
(Information provided in German, French and Italian)
Metadvice at the American Diabetes Association, Orlando
Metadvice will contribute to the American Diabetes Association 84th Scientific Sessions, 21-24 June 2024 in Orlando.
Entitled ‘Therapy Recommendation Neural Network for Comorbid Cardiometabolic Diseases’, the work discusses why a neural network can formulate therapy recommendations beyond clinical guidelines to improve comorbid outcomes for persons with type 2 diabetes in primary care.
Visit Poster #888-P at the event, and attend the General Poster Session, Sunday 23 June, 12:30-1:30pm.
Read the full abstract here.
Metadvice Chief Medical Officer, Professor Andrew Krentz elected Chair of the Academic Board at the Royal Society of Medicine
We are pleased to announce that Metadvice Chief Medical Officer, Professor Andrew Krentz, has been elected Chair of the Academic Board at the Royal Society of Medicine (RSM).
The Academic Board is responsible for delivering the academic and learning functions of the RSM by ensuring the Education Strategy is delivered through the RSM’s network of Sections, while improving education initiatives and programmes.
Professor Krentz, who will take up his new position in 2025, will become a Trustee of the RSM and will work closely with the incoming President, Professor Gillian Leng CBE, as well as the new Dean of Education and the RSM Council.
In his capacity as Chair-Elect, Professor Krentz said: “I am delighted and honoured to be elected Chair of the Academic Board at the Royal Society of Medicine. I look forward to working with my senior RSM colleagues to ensure a bright and sustainable future for this unique and treasured institution.”
About Andrew Krentz
Professor Andrew Krentz is a physician and clinical researcher. He trained at leading academic institutes in the UK and USA. His main clinical focus is the spectrum of cardiometabolic risk factor as drivers of vascular disease.
Among other current positions, Andrew is President Vascular, Lipid & Metabolic Medicine at the Royal Society of Medicine, and a member of the Scientific & Research Committee of the cholesterol charity HEART UK.
Metadvice CEO, Andrew Rut, Discusses AI in Healthcare for Open Access Government
Our CEO, Andrew Rut, has been featured in the April 2024 edition of Open Access Government, discussing the role AI can play in enhancing healthcare delivery and patient care.
The article is also available to read on the Open Access Government website.
New textbook on Insulin by our Chief Medical Officer, Andrew Krentz
Metadvice was extremely proud to see the publication of a new textbook, Insulin: Deficiency, Excess and Resistance in Human Disease, edited by our Chief Medical Officer, Andrew Krentz.
It was just over a century ago that insulin was discovered, and its lifesaving introduction to clinical practice was marked one of the most celebrated accomplishments of medical science.
The book offers a comprehensive guide to current and future therapeutic options via a focus on insulin deficiency and insulin resistance in human disease. Given that best clinical practice is based on a clear understanding of insulin pathophysiology (and how this leads to the disease states of type 1 diabetes, obesity-associated type 2 diabetes, cardiometabolic disease, cancer, and other relevant disorders) the timing of this publication is prescient.
Professor Krentz notes, “Living with type 1 diabetes remains exceedingly challenging for patients and families. Over the past century, type 2 diabetes has become a major cause of morbidity and premature mortality worldwide. Many aspects of care remain suboptimal, which means advances in precision medicine require clinicians and scientists to maintain their awareness across the spectrum of diseases.”
With four decades of clinical and translational research experience in metabolic, endocrine and related cardiovascular disorders, Andrew brings invaluable expertise to the Metadvice team. We wish him many congratulations on this new publication.
Metadvice’s CEO, Andrew Rut, is interviewed on BBC World News
In March 2024, our CEO, Andrew Rut, was interviewed for the BBC World News programme, World Business Report, by presenter Sally Bundock.
Andrew shared his insights about our work to optimise patient treatment and thus relieve the burden on healthcare systems across the globe. As he pointed out, “Most patients today with long term health issues suffer from more than one condition – AI and our software enable doctors to confidently manage the totality of a patient in a holistic way.”
Digital technologies are central to addressing the growing burden on global healthcare systems. We are at the forefront of using AI to redefine medical practice and reshape healthcare, enabling clinical teams to deliver targeted, evidence-based, and individualised treatments. Our mission is simple: to enable everyone to live healthier lives for longer.
Watch the full interview via LinkedIn.
How is AI transforming the pharma landscape? Metadvice CEO, Andrew Rut, on the Spencer Group Podcast
AI is not only fundamental to the design and execution of successful clinical trials, but also to ensuring patients receive the medicines they require.
In this podcast with Spencer Group CEO, Julian Minett, and Cisiv Ltd Chairman, Steve Powell, our CEO, Andrew Rut, discusses the impact of AI on the pharmaceutical landscape, and how it is addressing complex challenges posed by overlapping chronic diseases.
As Andrew shares, enhanced clinical decision making is critical to driving better health outcomes for patients – particularly those with complex comorbidities. By providing clinicians with tools that leverage the latest guidelines, along with refinements based on ‘digital twins’, we enable better, more transparent patient management.
Listen to the full episode above, or via the Spencer Group website.